Today in New Delhi, India
Jun 16, 2019-Sunday
New Delhi
  • Humidity
  • Wind

India to launch a national dengue survey to better combat the disease

India is set to conduct a National level survey, to know dengue’s prevalence in the country, and help devise better preventive measures.

india Updated: Mar 27, 2017 15:49 IST
Rhythma Kaul
Rhythma Kaul
Hindustan Times, New Delhi
Dengue,Dengue national survey,Mosquito-borne diseases
New Delhi, India - Sept. 21, 2016: Dengue and Chikungunya ward at Aruna Asaf Ali Hospital in New Delhi, India, on Wednesday, September 21, 2016. (Photo by Saumya Khandelwal/ Hindustan Times)(Saumya Khandelwal/HT PHOTO)

India is set to conduct a National level survey, to know dengue prevalence in the country.

Dengue is one of the most fatal mosquito-borne viral infections in the world, infecting lakhs of people and killing hundreds each year in India alone.

The exercise was planned after government’s apex body rejected to introduce the only vaccine against dengue in use globally, for use in India last year as there was no evidence to prove its efficacy in the Indian context.

“The vaccine works better if there is high anti-body rate within the community, and there was not enough India-specific data available for reference that raised safety concerns,” said Dr Soumya Swaminathan, director- Indian Council of Medical Research (ICMR).

“India is a vast country and we do not know much about the dengue pattern; which strain is common in which part of the country etc. There is a need to gather more information and the survey will help us do that.”

In 2016, 1,11,000 cases were reported and 227 people lost their lives to the mosquito-borne viral infection across India, government data shows.

This is despite state governments actively taking measures to control the spread of disease way before the onset of monsoon season, when the disease transmission is at its peak.

Experts at ICMR said there was limited data or clinical trials to assess the efficacy of the vaccine, therefore, could not have been given a green signal.

In May, the committee concerned had concluded that the data presented by the company was inadequate to show the efficacy and immunogenicity of the vaccine in Indians. Immunogenicity is the ability of a substance to provoke an immune response in the body.

However, the company’s spokesperson says that the Apex body did not reject their file. “The decision to waive local Phase III trial on Sanofi Pasteur dengue vaccine in India is currently under review by the regulatory authorities as we have resubmitted our file for reconsideration.”

The company resubmitted the application for dengue vaccine approval in June ’16. “In September 2016, the Technical committee, for the second time, gave a positive recommendation for approval. The subject was then discussed by the APEX body at the 32nd APEX Committee meeting, where the decision for approval was deferred,” the spokesperson said.

Meanwhile, the task of the dengue survey has been assigned to the National Institute of Epidemiology in Chennai, Tamil Nadu, which will lead the project. “The protocol for the survey is being developed currently, and we should be able to generate relevant data in about a year from now,” said Dr Swaminathan.

First Published: Mar 19, 2017 22:52 IST